Margot J. Burnell
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Advanced Breast Cancer Therapies
Most-Cited Works
- → Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.(1998)623 cited
- → Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer(2005)329 cited
- → Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial(2016)241 cited
- → Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer(2009)152 cited
- → Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study(1999)97 cited
- → Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial(2014)55 cited
- → Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials(2017)32 cited
- → A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer(2003)30 cited
- → Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial(2021)27 cited
- → A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)(2007)25 cited